Prevalence and determinants of chronic airflow obstruction in Khartoum State, Sudan

Rana Ahmed[1,3], Nada Osman[1,2], Rashid Kamal[1], Hana Elsadig[1], Hind Eltigani[1], Rebecca Nightingale[3], Jaymini Patel[4], Peter G. Burney[4], Kevin Mortimer[3], Asma ElSony[1,2]

[1]The Epidemiological Laboratory, Khartoum, Sudan

[2]WHO/EMRO Collaborating Centre for Tuberculosis and Lung Diseases, Khartoum, Sudan

[3]Liverpool School of Tropical Medicine, Liverpool, UK

[4]Imperial College, London, UK

Correspondence and requests for reprints: Asma ElSony
Director, Head of Scientific Activities at the Epidemiological Laboratory, WHO/EMRO Collaborating Centre for TB and Lung Diseases, PO Box 10012, Khartoum, Sudan
Phone/Fax: +24 91 5515 2445
E-mail: asmaelsony@gmail.co

Take Home Message
Chronic lung disease and CAO are serious problems in adults in urban Sudan

Abstract [239 words]

This study estimates the prevalence of chronic pulmonary disease defined by spirometry in urban Khartoum and identifies the impact of risk factors on the prevalence of disease.

Nine hundred and ninety-eight subjects aged 40 years or older from three localities in Khartoum were enrolled in this cross-sectional survey. A field worker collected questionnaire data and performed pre- and post-bronchodilator spirometry tests. Survey-weighted prevalence estimates of respiratory symptoms and spirometric abnormalities were computed. Bivariate and multivariable regression analyses were used to identify associated variables.

Full questionnaire and spirometry data were collected from 516 subjects. Using the National Health and Nutrition Examination Survey 1988–1994 reference range for white Americans, the prevalence of Chronic Airflow Obstruction (CAO) according to lower limit of normal (LLN) was 10% (standard error [SE] 1.4). The main risk factor for CAO was older age of 60-69 years (odds ratio 3.16, 95% confidence interval 1.20-8.31). Other risk factors such as low level of education, high body mass index and having history of tuberculosis were also identified. The prevalence of a low forced vital capacity (FVC) using the NHANES reference range was 62.7% (SE 2.2) and 11.3% [SE 1.4] using internally derived local values.

The prevalence of spirometric abnormality; mainly (low FVC) was high suggesting that chronic lung disease is of substantial public health importance in urban Sudan. Consideration from the public health and health system strengthening for the prevention and control of these problems is highly needed.

Introduction

The Global Burden of Disease Study estimates 3.9 million deaths annually from chronic non-communicable respiratory diseases [1]. According to the World Health Organization, these diseases are expected to be responsible for the largest increase in global mortality in upcoming decades [2, 3]. Approximately 80% of all deaths from non-communicable diseases occur in low-income and middle-income countries. Of these almost 12% are due to chronic non-communicable respiratory diseases, in particular chronic obstructive pulmonary disease (COPD) [1, 2] which is now the third most common cause of death globally [4, 5].

There has been little research on COPD in Africa outside of South Africa. The prevalence estimates for COPD in sub-Saharan Africa [6–8] are based on limited epidemiological data which lack a standardized definition of COPD. A systematic review by Finney et al. in 2013, reported only 9 cross-sectional studies from sub-Saharan Africa (2 from South Africa, 2 from Nigeria, one from Malawi, and one from Cape Verde). These studies used various diagnostic methods and found a prevalence of COPD ranging from 4.1% to 24.8% [9].

The Burden of Obstructive Lung Disease (BOLD) Initiative was established to develop standardized methods for estimating the prevalence of COPD and associated risk factors in the population aged 40 years and older [10, 11]. It also aims to measure the influence of COPD on quality of life, ability to perform activities of daily living, respiratory symptoms, and use of health care services [11, 12]. Results from local BOLD studies in Africa have so far been published from Fez in Morocco, [13] Sousse in Tunisia, [14, 15] Blantyre in Malawi [16] and Ile-Ife in Nigeria[17].

To date, there are no published data on the prevalence and determinants of Chronic Airflow Obstruction (CAO) and COPD in Sudan. To help fill this knowledge gap, we conducted a population-based, cross-sectional BOLD study of the prevalence of CAO in urban Khartoum and the impact of risk factors on disease prevalence.

Materials and methods

Sudan lies in North East Africa. Its capital Khartoum is situated in Khartoum state which in turn is divided into 7 localities, across which there is a mix of urban, semi-urban, rural, and internally displaced populations. The total population of Khartoum state is 5,274,321. Three of the 7 localities, with a total population of 661,617, were randomly selected for sampling in this study. Clusters were formed within each locality, comprising 19 in Jabel Awlya, 17 in Sharg Alneel, and 11 in Omdurman. Each cluster was comprised of 15 households. A total of 280, 258 and 158 households were then randomly selected from Jabel Awlya, Sharg Alneel and Omdurman respectively.

The study participants were aged 40 years or older and were selected using a 3-stage stratified cluster sampling plan. The exclusion criteria were; age younger than 40 years, being institutionalized (e.g., living in a community-based care centre or incarcerated in prison), and being medically unfit to perform spirometry (e.g., pregnant women in their third trimester and individuals with a history of myocardial infarction or major surgery in the previous 3 months).

All study participants completed a structured interview administered by a trained interviewer. Anthropometric measurements along with pre-bronchodilator and post-bronchodilator spirometry data were then collected in accordance with the American Thoracic Society guidelines using an Easy One system (ndd Medizintechnik, Zurich, Switzerland) by three trained certified technicians in accordance with the BOLD protocol [11]. The questionnaire was administered in the local language (Arabic) and included questions about respiratory symptoms, medical history, medications, smoking history, use of biomass fuel, and occupational exposure. Where participants were not willing to participate in the full study, a minimal data or refusal questionnaire was obtained. The clinical data obtained included height, weight, pulse rate, and waist and hip circumference. Quality control was carried out at the central BOLD centre. Usable spirometry was defined as two or more acceptable blows, with FEV1 and FVC repeatability within 200 mL. Acceptable manoeuvres were defined as those with a rapid start (back-extrapolated volume, 150 mL or 5% of the FVC), lack of a cough during the first second, and a small end-of-test volume (,40 mL during the final second). The calibration of all spirometers was verified to be accurate within 3.0% using a 3.00 L syringe at the beginning of each day of testing. Spirometry traces were then classified

according to FEV1/FVC < lower limit of normality (LLN) in an age-matched healthy reference group of the studied population.

Preselection and randomization of areas and households were carried out before the field visits. All the selected houses in each area were consecutively numbered. Within those households, all eligible adults aged 40 years or older were interviewed.

Each participant package had a unique 6-digit identifier that contained both the country and the city code. All study data were then pseudo-anonymised and entered in the BOLD online platform of Imperial College, London.

In accordance with the BOLD project protocol[11], we set out to include a sample size of 600 participants aged 40 years or older who were stratified according to sex and age.

Definition

CAO was defined by post bronchodilator (BD) FEV1/FVC below the lower limit of normal (LLN). Predicted values based on standardized values for age, sex, and height were calculated based on the Third National Health and Nutrition Examination Survey 1988–1994 (NHANES III) of white Americans [18] while the local values were derived from spirometry of non-smoking Sudanese adults with no respiratory symptoms or diagnoses participating in this survey. CAO stages were categorised as: stage 1 or higher CAO (Post-BD FEV1/FVC < LLN) and stage 2 or higher CAO (Post-BD FEV1/FVC < LLN and post-BD FEV1 < 80% predicted).

Statistical analysis

A comparison between groups with an assessment of selection bias was conducted using chi-square test between subjects who completed full data and minimal questionnaires with acceptable or unacceptable spirometry readings. Prevalence estimates of spirometric abnormalities stratified by subject age and sex were reported using the NHANES III reference range [11]. In addition, prevalence estimates were also reported using locally derived spirometry ranges for non-smoking Sudanese adults with no history of respiratory disease or symptoms.

Univariate and logistic regression analyses were used to test the associations between spirometry abnormalities and several exposure variables, including age, sex, education

level, self-reported history of tuberculosis (TB), hypertension, diabetes, and/or heart disease, body mass index, smoking status, smoking pack-year exposure, exposure to indoor biomass fuel, and occupational exposure.

A wealth score has been developed based on a Mokken scale, which is based on a count of assets owned by the study subjects and ranked for their ability to differentiate between different levels of wealth [19]. This has been developed based on previous studies by Townend *etal* [19, 20].

Multivariable logistic regression models that included sex, age, and all variables from the univariate analysis with a *p*-value <0.2 were then developed. The prevalence of respiratory symptoms was reported and associations with the study variables were tested using regression analysis. A description of the associations between abnormal spirometry and respiratory symptoms is reported. The data were analysed using Stata IC 16 (StataCorp, College Station, TX). Prevalence estimates and regression models were developed using survey weighting with the Svy package in Stata (14).

Both univariate and multivariate analysis were reported for the prevalence estimates using below Lower Limit of Normal(LLN) standards.

Ethical approval was obtained from the Imperial College London and the Ministry of Health in Khartoum state ethics committee prior to the start of the study. All participants gave written informed consent prior to any data being collected.

Results

The flow of subjects through the study is shown in Figure 1. Of the 998 participants approached, 300 were not traceable, 698 were interviewed, and 516 provided full questionnaire data and had BOLD centre-approved spirometry results. Eleven of the 698 subjects declined to participate fully in the study but completed the minimal data questionnaire while 2 were ineligible. Fifty-four (7.74%) of the eligible subjects provided only spirometry readings. The final response rate was 85.5% (n=696).

Subject characteristics

The characteristics of the subjects are presented in Table 1. Their mean age was 53.8 ± 10.4 years and 59.3% were men.. Overall, 35% completed primary school education. Men tended to have a higher level of education compared to women, as did the group aged 40–49 years when compared to other age groups. The mean number of household members was 7.8 ± 3.56 and the mean wealth score was 5.2 ± 2.7. Eligible individuals who refused to participate but provided minimal data were 1.82%

TABLE 1

Characteristics of all subjects who completed a full BOLD core questionnaire, including those with and without spirometry results

Variable (n)	n (%)
Age group, years (n=595)	
40–49	226 (38.0)
50–59	200 (33.6)
60–69	108 (18.2)
70+	61 (10.3)
Sex (n=595)	
Male	353 (59.3)
Female	242 (40.7)
Level of education (n=593)	
None	125 (21.1)
Primary school	207 (34.9)
Middle school	69 (11.6)
High school or above	192 (32.4)
Mean years of education (n=595)	6.49 (5.5)
Smoking status (n=595)	
Current smoker	55 (9.2)
Ex smoker	86 (14.5)
Never smoked	454 (76.3)
Pack-years of smoking (n=595)	
Never smoked	454 (76.3)
0 -10	71 (11.9)
10-20	36(6.1)
≥20	34(5.7)
Biomass exposure (n=532)	
Yes	422 (82.4)
No	90 (17.6)
Farm work for ≥3 months (n=527)	
Yes	126 (23.9)
No	401 (76.1)
Body mass index (n=588)	
Underweight (<18.5)	39 (6.6)
Normal (18.5–24.9)	226 (38.4)
Overweight (25.0–29.9)	189 (32.1)

Obese (≥30)	134 (22.8)
Reported history of tuberculosis (n=595)	
Yes	5 (0.8)
No	590 (99.2)
Reported history of hypertension (n=595)	
Yes	118 (19.8)
No	477 (80.2)
Reported history of diabetes (n=595)	
Yes	54 (9.1)
No	541 (90.9)
Reported history of heart disease (n=595)	
Yes	12 (2.0)
No	583 (98.0)

Environmental Exposures

Among the respondents, 24% had smoked cigarettes. Fifteen percent of men and 0.8% of women were current smokers. About (24%) of smokers had more than a 20 pack-years of exposure. Exposure to indoor biomass fuel for more than 6 months was reported by 82% of subjects. In total, 78% reported having used an indoor open fire fuelled by coal or charcoal for cooking for ≥6 months, while 35% used firewood and 21% used kerosene. Overall, women tended to have a higher mean number of hours of exposure to indoor biomass fuel per year than men (70% vs. 54%). Farming was the most commonly reported occupation (in 24%, Table 1).

Other diseases

In total, 23% of subjects were obese and 7% were underweight. Hypertension was self-reported by 20% of all subjects, of whom 55% were women. Diabetes was reported by 9% (9.5% of women and 8.8% of men), heart disease by 2% (2.3% of women and 1.7% of men), lung cancer by 0.5%, stroke by 0.5%, and TB by 0.8% (1.2% of women and 0.6% of men). None of these diseases were associated with any type of obstruction or low FVC using either local or NHANES reference ranges except having tuberculosis associated with CAO stage 1 or higher using the NHANES reference range (OR 0.08, 95% CI 10.01- 0.59).

Respiratory symptoms

At least one respiratory symptom was reported by 23% (SE 1.9) of subjects; respiratory symptoms interfering with daily activities was reported by 1.9% (SE 0.5). Cough was reported by 10.4% (SE 1.3), with the highest prevalence recorded in subjects aged 70+

years (11.9% [SE 4.9]). The prevalence of cough was higher in men than in women (10.6% [SE 1.6] vs. 10.1% [SE 2.0]. Chronic cough (lasting for more than 3 months per year) was reported by 4.0% (SE 0.8) of the study population. Production of sputum was reported by 11% (SE 1.3) and chronic production of sputum (for more than 3 months per year) was reported by 5% (SE 0.09). Shortness of breath was reported by 11% (SE 1.3) and 41% (SE 6.5) of this group stopped walking after 100 yards because of breathing problems. Wheeze in the past 12 months in the absence of a cold was the least commonly reported symptom (3.0% [SE 0.7], Supplementary Table S1 and Figure 2). A significant positive correlation was found between all respiratory symptoms ($p<0.05$, Pearson's r correlation).

Spirometry

No statistically significant differences were found between the groups who did or did not complete the spirometry test (Supplementary Table S2). Using NHANES III, LLN stage 1 or higher CAO prevalence was 10.3% [SE 1.4] (9.2[SE 1.7] of men and 11.2[SE 2.4] of women). On other hand using the locally derived reference range the prevalence was 5.7% [SE 1.1] (5.2% [SE 1.3] of men and 6.25[SE 1.9] of women)

Subjects aged 60–69 years had the highest prevalence of stage 1 or higher CAO (13.4% [SE 3.8]). Prevalence of stage 2 or higher CAO was 9.4% [SE 1.4) (8.8%[SE 1.7] of men and 10.1% [SE 2.2] of women). Using the locally derived reference range, 3.0% [SE 0.8] of the study population had stage 2 or higher CAO (2.9% [SE 0.9] of men and 3.1% [SE 1.3] of women). Similarly, subjects aged 60–69 years had the highest prevalence of stage 2 or higher CAO using both the local and NHANES reference ranges (17.6% [SE 4.2] vs. 6.7% [SE 2.6]).

Low FVC according to LLN and NHANESIII estimates was prevalent in 62.7% [SE 2.2] (65.2% [SE 2.8] in men vs. 59.8% [SE 3.5] in women).

Cough was less commonly reported in those with low FVC (odds ratio [OR] 0.48, 95% confidence interval [CI 0.27-0.87]). There was no other significant association between spirometric abnormality and respiratory symptoms. Airway reversibility was found in 6.1% [SE 1.1] of the total study population and was more prevalent in women than in men (8% [SE 1.9] vs. 4.4% [SE 1.1]). Airway obstruction persisted after use of a

bronchodilator in 8.4% (SE 4.7) of subjects with reversibility.(Supplementary Table S3 & S4, Figure 3)

Factors associated with respiratory symptoms

There was no significant association between cough and any of the risk factors investigated in either bivariate or multivariate analysis.

In both multivariate and bivariate analyses, regular production of sputum was negatively associated with age (Supplementary Tables S3 and S4). Subjects aged 60–69 years were less likely to report regular sputum production (OR 0.39, 95% CI 0.16–0.93) than those aged 40–49 years. There was a significantly increased likelihood of regular sputum production with being an ex-smoker (OR 2.66, 95% CI 1.09–6.50) and having diabetes (OR 4.04, 95% CI 1.82–8.96). There was no observed trend in Mokken scale points and all respiratory symptoms. However, participants with lower socioeconomic status; who have a wealth score of 2 as well as participant with a score of 7 tend to have higher odds of sputum production compared to those with zero score (OR 7.18, 95% CI 1.16-44.53 and OR 4.83, 95% CI 1.05- 22.17 respectively).

In multivariate analysis, the likelihood of having shortness of breath was significantly greater in subjects exposed to indoor biomass fuel (OR 4.56, 95% CI 1.44–14.43). The presence of wheeze was only associated with being a current smoker (OR 3.49, 95% CI 1.02–11.96). There were no significant associations between CAO and respiratory symptoms.

Factors associated with post-bronchodilator airway obstruction

Subjects aged 60–69 years had the highest risks of CAO stage 1 or higher (OR 3.16, 95% CI 1.20-8.31) and stage 2 or higher (OR 3.39, 95% CI 1.04- 6.93) than those aged 40–49 years. In contrast, having higher education level was protective against any obstruction in bivariate analysis (OR 0.31, 95% CI 0.13–0.76), however no association was identified after adjustment. Similarly, being overweight or obese was protective against any obstruction (OR 0.38, 95% CI 0.17–0.82 and OR 0.34, 95% CI 0.13–0.99, respectively). Those with a history of TB were less likely to have any obstruction (OR 0.08, 95% CI 0.01- 0.59). There was no observed trend in Mokken scale points and CAO. However, participants with a low socioeconomic position who scored ≥2 in

wealth score had the highest odds of developing stage 1 or higher and stage 2 or higher CAO (OR 6.00, 95%CI 1.03-34.94). No other factor was significantly associated with airway obstruction (Tables 2 and 3, Supplementary Tables S5 and S6).

Using the local reference range, subjects aged 60–69 years were more likely to have CAO stage 1 or higher than their younger counterparts (OR 3.10, 95% CI 1.01- 9.57), and being obese were negatively associated with obstruction (OR 0.29, 95% CI 0.09-0.97) in multivariable analysis. Having higher education level was protective against CAO in the bivariate analysis (OR 0.23, 95% CI 0.063 - 0.83) however no association was identified after adjustment. Using firewood for cooking for more than 6 months was protective against CAO stage 2 or higher (OR 0.11, 95% CI 0.03 - 0.44) in bivariate analysis however no association identified after adjustment. No other association was seen between possible risk factors and abnormal spirometry.

TABLE 2

Multivariable associations of risk factors with CAO defined using NHANES III (Post-BD FEV1/FVC < LLN ; n=64/590)

Variable	Multivariable association	
	OR	95% CI
Age group, years		
40–49	1.0	-
50–59	2.13	0.84 - 5.41
60–69	3.16 *	1.20 - 8.32
70+	1.91	0.60- 6.10
Sex		
Male	1.0	-
Female	1.31	0.61- 2.84
Level of education		
None	1.0	-
Primary school	0.61	0.27- 1.34
Middle school	1.23	0.40- 3.81
High school or above	0.71	0.28- 1.78
Body mass index		
Underweight (<18.5)	1.87	0.66- 5.30
Normal (18.5–24.9)	1.0	-

Overweight (25.0–29.9)	0.43	0.18-1.01
Obese (≥30)	0.35	0.11- 1.17
Self-reported TB		
No	1.0	-
Yes	0.08	0.01- 0.59

*$p<0.05$. CI, confidence interval; OR, odds ratio; FEV_1, forced expiratory volume in 1 second; FVC, forced vital capacity ratio; LLN, lower limit of normal

TABLE 3

Multivariable associations of risk factors with Stage 2 or higher CAO defined using NHANES III (Post-BD FEV1/FVC < LLN and post-BD FEV1 < 80% predicted; n=58/590)

Variable	Multivariable association	
	OR	95% CI
Age group, years		
40–49	1.0	-
50–59	1.86	0.73- 4.77
60–69	2.78*	1.07- 7.26
70+	0.91	0.21-3.92
Sex		
Male	1.0	-
Female	1.67	0.76- 3.66
Level of education		
None	1.0	-
Primary school	0.62	0.27- 1.44
Middle school	1.03	0.32-3.36
High school or above	0.69	0.26- 1.86
Body mass index		
Underweight (<18.5)	1.16	0.33-4.07
Normal (18.5–24.9)		
Overweight (25.0–29.9)	0.37*	0.15-0.92
Obese (≥30)	0.29*	0.08- 1.07
Self-reported TB		
No	1.0	0
Yes	0.07*	0.01- 0.48
Number of people living in household	1.05	0.96-1.16
Used firewood		
No	1.0	-
Yes	0.58	0.29- 1.19
Wealth score/Mokken scale	0.96	0.83-1.11

Factors associated with low FVC

Using the NHANES III, low FVC was associated with smoking 10-20 packs year history, having primary or higher level education, having more people in house and being obese (OR, 2.79, 95% CI 1.11- 7.00; OR 2.42, 95% CI, 1.43- 4.09; OR 0.94, 95% CI 0.89-0.99 and OR 1.73,95% CI, 1.04-2.86 respectively) in bivariate analysis. In multivariate analysis, those aged 50-59 were less likely to have low FVC compared to those aged 40-49 years (OR 0.52 ,95%CI, 0.32-0.84). No other factors were associated with low FVC in multivariate analysis. (Table 4)

TABLE 4

Multivariate associations of risk factors with low FVC, defined using NHANES III reference range (FEV1/FVC ratio >LLN and FVC <LLN), n= 353/590, all obstructed people excluded

Variable	Multivariable association	
	Odds ratio	**95% CI**
Age group		
40-49	1	-
50-59	0.53*	0.32-0.91
60-69	0.32*	0.17-0.59
70+	0.23*	0.11-0.50
Gender		
Male	1	-
Female	0.83	0.50-1.40
Body Mass Index (kg/m2)		
Underweight (BMI<18.5)	1.40	0.55-3.54
Normal (BMI 18-25)	1	-
Overweight (BMI 25-30)	1.17	0.68-2.01
Obese (BMI >30)	1.26	0.68-2.34
Packs-year of smoking		

Never	1	-
0-10	1.30	0.66-2.54
10-20	2.31	0.68-7.82
≥20	0.91	0.40-2.04
Wealth score/Mokken scale	0.97	0.88-1.07
*indicates p<0.05		

Discussion

In this population-based cross-sectional study, we aimed to investigate the determinants of prevalence of COPD and the main risk factors for the disease in the population aged 40 years and older in urban Sudan. Our main finding was that 10 % of people in this age group had spirometric findings compatible with COPD using the LLN definition. A high prevalence of low FVC (62.7%) was identified using the NHANES III reference range for Caucasian Americans. CAO stage II or higher was detected in 9.4% of the overall population using the same reference range, though this decreased to 3.0% when the local reference range was used.

Our finding of a higher prevalence of obstruction when using the NHANES III reference range compared to the local reference range has been reported previously [16]. The NHANES III reference range is a standardized validated set of spirometric measurements for asymptomatic, Caucasian, non-smoking Americans and adjusted for age, sex, and height. In the present study, the local ranges reported are based on heathy non-smoking Sudanese adults participated in this study. In spite of it being the only available data, values of the local methodology might be ethnically more suitable compared to NHANES, however, different exposures in this settings may constrain it [16].

There is a lack of evidence to explain the finding of low FVC in this population. However, low FVC has been reported in other BOLD research in sub-Saharan Africa [16]. Our findings are consistent with other studies in resource-poor settings, but the literature in this area is still limited and there is still no valid explanation [21]. However, unidentified environmental factors, low birth weight, early exposure to biomass fuel and air pollution and poor diet are common factors associated with lung restriction in developing countries [21].

The prevalence of spirometric obstruction in our study is consistent with that in similar studies from sub-Saharan Africa, where the prevalence of smoking is high [9, 22]. Previous BOLD studies reported COPD prevalence of 23% in men and 16.9% in women in South Africa [21] and 7.7% in Nigeria [9, 17, 23]. CAO prevalence reported from a recent multinational BOLD study was 11.5% in men and 8.8% in women which is consistent with our findings[24]. In addition, the median reported prevalence in Africa in a recent systematic analysis of spirometric-based studies was 13.4%, which is in line with our results [22]. When compared with studies from the MENA region (Middle East and North Africa), our findings for the prevalence of CAO are higher than those in Saudi Arabia [25], Abu Dhabi[26], Tunisia,[14, 27] Morocco,[13] Algeria,[28] and Lebanon [29].

Older age was the main risk factor for CAO in our study, which is consistent with both regional and global findings [9, 16, 22, 23, 30]. The age group 60-69 years had the highest prevalence estimates of spirometric obstruction using LLN definitions. This age group also reported a higher prevalence of both chronic cough and chronic phlegm, This might be because of a higher smoking prevalence when compared to other age groups. In addition, Using the NHANES III reference range, younger age protected against low FVC.

A higher educational level was protective against CAO which is compatible with other studies [10, 23, 31]. The absence of an association with spirometric obstruction and cigarette smoking might not be the result of heavy smoking, given that 50% of the smokers in our study reported a smoking history of less than 10 pack-years. Countries with lower smoking rates, such as Malawi and Rwanda, have a lower reported prevalence of COPD [16, 32].

The association between low FVC and high BMI is consistent with previous studies reported that obesity is a cause of low FVC as a result of restriction coming from the accretion of body fat [33].

Conversely, we found a significant association between the low socioeconomic status, identified by the wealth score, and developing post bronchodilator airway obstruction using LLN. Participants who owned one asset and having the lowest wealth score tend to have higher odds of developing CAO. This is consistent with other studies suggesting

that low socioeconomic status may be associated with a progression of airflow limitation [22, 34].

The lack of a significant association between greater numbers of people per household and either obstruction or low FVC is in contrast with other studies suggesting that crowded housing and low socioeconomic status may be associated with progression of airflow limitation [22, 34]. A possible reason for this difference may be due to the low intensity of environmental exposure in this setting.

We did not observe any association between occupational exposure and obstruction. Twenty-three percent of the subjects in this study were farmers and no association with lung disease was observed. Further, no association between exposure to biomass fuel and obstruction was identified except having the use of firewood for more than 6 months in cooking inversely associated with CAO stage 2 or higher using the local reference range. This is in contrast with the published reports of exposure to biomass fuel being the biggest risk factor for lung disease in Africa [6, 7, 9, 22]. However, a recent study that included 25 BOLD sites stated that airflow obstruction measured by post-bronchodilator spirometry was not associated with use of solid fuels for cooking or heating, [35] a finding in three other large studies in China[36–38]. Although causality cannot be assumed from this cross-sectional study, it seems reasonable that a positive association would be found in this high-use population. However, it is plausible that people using biomass fuel would experience more symptoms, such as shortness of breath, which is considered as one of the most common symptoms of CAO. It is possible that this group of patients suffer from chronic bronchitis or similar non-obstructive lung diseases. In addition, the finding that only 0.2% reported TB might account for the significant negative association between TB and obstruction, which again is in conflict with the published literature [39]. Identification of TB was based on self-reporting, and many factors might affect the validity of the answers provided, given that TB is a highly stigmatized clinical condition and the proportion reported here may be an underestimate [40].

A strength of our study is that it is the first we are aware of to provide prevalence estimates of CAO in Sudanese adults using internationally standardised methods and

procedures as well as an appropriate sampling technique. Following the BOLD project protocol will allow for future comparisons with other COPD studies.

A limitation of our study is that missing information for a proportion of the study participants limited the cluster-weighted analysis. Furthermore reasons for exclusion were not recorded, meaning those who were excluded for medical reasons were not separated from those who were excluded for other reasons. Having spirometry reading only with no matching questionnaire data for 54 participants and unacceptable spirometry readings from 79 participants decreased our sample size and study power.

In conclusion, this study found that chronic lung disease is a significant problem in Sudan and needs to be considered in future public health policies. The overall prevalence of CAO in urban Sudan is similar to that found by other BOLD centres in countries with similar smoking rates, such as South Africa, but relatively high when compared with other countries in sub-Saharan Africa and the MENA regions. A high prevalence of low FVC was also identified, the aetiology and pathophysiology of which is unknown and requires further investigation. Taken together these findings suggest the need for strengthening of smoking cessation programmes and provision of improved diagnostic and treatment options for chronic respiratory disease.

Acknowledgements
We thank the members of the BOLD Coordinating Centre at the Imperial College London for its assistance with spirometry training, quality control, and data management in the study. We also thank the teams of data collectors and spirometry technicians from Sudan for their hard work during the household survey.

References

1. Wang H, Naghavi M, Allen C, Barber RM, Bhutta ZA, Carter A, Casey DC, Charlson FJ, Chen AZ, Coates MM, Coggeshall M, Dandona L, Dicker DJ, Erskine HE, Ferrari AJ, Fitzmaurice C, Foreman K, Forouzanfar MH, Fraser MS, Fullman N, Gething PW, Goldberg EM, Graetz N, Haagsma JA, Hay SI, Huynh C, Johnson CO, Kassebaum NJ, Kinfu Y, Kulikoff XR, et al. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet* 2016; 388: 1459–1544.
2. de-Graft Aikins A, Unwin N, Agyemang C, Allotey P, Campbell C, Arhinful D. Tackling Africa's chronic disease burden: from the local to the global. *Global. Health* 2010; 6: 5.
3. World Health Organization. Global action plan for the prevention and control of noncommunicable diseases 2013-2020. World Heal. Organ. 2013. p. 102.
4. Tan WC, Vollmer WM, Lamprecht B, Mannino DM, Jithoo A, Nizankowska-Mogilnicka E, Mejza F, Gislason T, Burney PGJ, Buist AS. Worldwide patterns of bronchodilator responsiveness: results from the Burden of Obstructive Lung Disease study. *Thorax* 2012; 67: 718–726.
5. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, AlMazroa MA, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Barker-Collo S, Bartels DH, Bell ML, Benjamin EJ, Bennett D, Bhalla K, Bikbov B, Abdulhak A Bin, Birbeck G, Blyth F, Bolliger I, Boufous S, Bucello C, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 2012; 380: 2095–2128.
6. Salvi S. The silent epidemic of COPD in Africa. *Lancet Glob. Heal.* 2015; 3: e6–e7.
7. Mannino DM. COPD in Africa: the coming storm. *Int. J. Tuberc. Lung Dis.* 2013; 17: 572.
8. Zaraket H, Charide R, Kreidieh K, Dbaibo G, Melhem NM. Update on the epidemiology of rotavirus in the Middle East and North Africa. *Vaccine* 2017; 35: 6047–6058.
9. Finney LJ, Feary JR, Leonardi-Bee J, Gordon SB, Mortimer K. Chronic obstructive pulmonary disease in sub-Saharan Africa: a systematic review [Review article]. *Int. J. Tuberc. Lung Dis.* 2013; 17: 583–589.
10. Buist a. S, Vollmer WM, McBurnie M a. Worldwide burden of COPD in high- and low-income countries. Part I. The Burden of Obstructive Lung Disease (BOLD) Initiative. *Int. J. Tuberc. Lung Dis.* 2008; 12: 703–708.
11. Buist AS, Vollmer WM, Sullivan SD, Weiss KB, Lee TA, Menezes AMB, Crapo RO, Jensen RL, Burney PGJ. The Burden of Obstructive Lung Disease Initiative (BOLD): rationale and design. *COPD* Taylor & Francis; 2005; 2: 277–283.
12. Rutten-van Molken M. Raising the awareness: projecting the future burden of COPD with the BOLD model. *Eur. Respir. J.* 2009; 34: 787–789.
13. El Rhazi K, Nejjari C, BenJelloun MC, El Biaze M, Attassi M, Garcia-Larsen V. Prevalence of chronic obstructive pulmonary disease in Fez, Morocco: results from the BOLD study. *Int. J. Tuberc. Lung Dis.* 2016; 20: 136–141.
14. Daldoul H, Denguezli M, Jithoo A, et al. Prevalence of COPD and tobacco smoking in Tunisia - Results from the BOLD study. *Int. J. Environ. Res. Public*

Health 2013; 10: 7257–7271.

15. Denguezli M, Daldoul H, Harrabi I, Chouikha F, Ghali H, Burney P, Tabka Z. Prevalence and Characteristics of Undiagnosed COPD in Adults 40 Years and Older–Reports from the Tunisian Population-Based Burden of Obstructive Lung Disease Study. *COPD J. Chronic Obstr. Pulm. Dis.* Taylor & Francis; 2020; 0: 1–8.

16. Meghji J, Nadeau G, Davis KJ, Wang D, Nyirenda MJ, Gordon SB, Mortimer K. Noncommunicable lung disease in sub-Saharan Africa a community-based cross-sectional study of adults in urban Malawi. *Am. J. Respir. Crit. Care Med.* 2016; 194.

17. Obaseki DO, Erhabor GE, Gnatiuc L, Adewole OO, Buist SA, Burney PG. Chronic Airflow Obstruction in a Black African Population: Results of BOLD Study, Ile-Ife, Nigeria. *COPD J. Chronic Obstr. Pulm. Dis.* 2016; 13: 42–49.

18. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. Population. *Am. J. Respir. Crit. Care Med.* 1999; 159: 179–187.

19. Townend J, Minelli C, Harrabi I, Obaseki DO, El-Rhazi K, Patel J, Burney P. Development of an international scale of socio-economic position based on household assets. *Emerg. Themes Epidemiol.* BioMed Central; 2015; 12: 1–11.

20. Townend J, Minelli C, Mortimer K, Obaseki DO, Al Ghobain M, Cherkaski H, Denguezli M, Gunesekera K, Hafizi H, Koul PA, Loh LC, Nejjari C, Patel J, Sooronbayev T, Buist SA, Burney PGJ. The association between chronic airflow obstruction and poverty in 12 sites of the multinational BOLD study. *Eur. Respir. J.* 2017; 49.

21. Burney P, Jithoo A, Kato B, et al. Chronic obstructive pulmonary disease mortality and prevalence: the associations with smoking and poverty—a BOLD analysis. *Thorax* 2014; 69: 465–473.

22. Adeloye D, Basquill C, Papana A, Chan KY, Rudan I, Campbell H. An Estimate of the Prevalence of COPD in Africa: A Systematic Analysis. *COPD J. Chronic Obstr. Pulm. Dis.* 2015; 12: 71–81.

23. Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study. *Lancet* 2007; 370: 741–750.

24. Burney P, Patel J, Minelli C, Gnatiuc L, Amaral AFS, Kocabaş A, Cherkaski HH, Gulsvik A, Nielsen R, Bateman E, Jithoo A, Mortimer K, Sooronbaev TM, Lawin H, Nejjari C, Elbiaze M, El Rhazi K, Zheng J-P, Ran P, Welte T, Obaseki D, Erhabor G, Elsony A, Osman NB, Ahmed R, Nizankowska-Mogilnicka E, Mejza F, Mannino DM, Bárbara C, Wouters EFM, et al. Prevalence and Population Attributable Risk for Chronic Airflow Obstruction in a Large Multinational Study. *Am. J. Respir. Crit. Care Med.* American Thoracic Society - AJRCCM; 2020; .

25. Al Ghobain M, Alhamad EH, Alorainy HS, Al Kassimi F, Lababidi H, Al-Hajjaj MS. The prevalence of chronic obstructive pulmonary disease in Riyadh, Saudi Arabia: a BOLD study. *Int. J. Tuberc. Lung Dis.* 2015; 19: 1252–1257.

26. Al Zaabi A, Asad F, Abdou J, Al Musaabi H, Al Saiari MB, Mohammed Buhussien AS, Nagelkerke N, Soriano JB. Prevalence of COPD in Abu Dhabi, United Arab Emirates. *Respir. Med.* 2011; 105: 566–570.

27. Denguezli M, Daldoul H, Harrabi I, et al. COPD in Nonsmokers: Reports from the Tunisian Population-Based Burden of Obstructive Lung Disease Study.

PLoS One 2016; 11: e0151981.

28. Hacene Cherkaski H, Khalloufi F, Atoui F, Yakoubi R, Gnatiuc L, Burney P, Benali R. The prevalence of COPD in Annaba, Algeria: Results of the BOLD study. *Eur. Respir. J.* 2014; 44.

29. Ben Abdallah FC, Taktak S, Chtourou A, Mahouachi R, Kheder A Ben. Burden of Chronic Respiratory Diseases (CRD) in Middle East and North Africa (MENA). *World Allergy Organ. J.* 2011; 4: S6-8.

30. Rimland JM, Abraha I, Luchetta ML, et al. Validation of chronic obstructive pulmonary disease (COPD) diagnoses in healthcare databases: a systematic review protocol. *BMJ Open* 2016; 6: e011777.

31. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. *Lancet* 2007; 370: 765–773.

32. Musafiri S, Joos G, Van Meerbeeck JP. Asthma, atopy and COPD in sub-Saharan countries: the challenges. *East Afr. J. Public Health* 2011; 8: 161–163.

33. Obaseki DO, Erhabor GE, Awopeju OF, Adewole OO, Adeniyi BO, Buist EAS, Burney PG. Reduced forced vital capacity in an African population prevalence and risk factors. *Ann. Am. Thorac. Soc.* 2017; 14: 714–721.

34. Lamprecht B, McBurnie MA, Vollmer WM, Gudmundsson G, Welte T, Nizankowska-Mogilnicka E, Studnicka M, Bateman E, Anto JM, Burney P, Mannino DM, Buist SA. COPD in never smokers: Results from the population-based burden of obstructive lung disease study. *Chest* 2011; 139: 752–763.

35. André FSA, Jaymini P, Bernet SK, Al E. Airflow obstruction and use of solid fuels for cooking or heating: BOLD results. *Am. J. Respir. Crit. Care Med.* 2017; 182: 745–751.

36. Smith M, Li L, Augustyn M, Kurmi O, Chen J, Collins R, Guo Y, Han Y, Qin J, Xu G, Wang J, Bian Z, Zhou G, Peto R, Chen Z. Prevalence and correlates of airflow obstruction in ,317 000 never-smokers in China. *Eur. Respir. J.* 2014; 44: 66–77.

37. Wang C, Xu J, Yang L, Xu Y, Zhang X, Bai C, Kang J, Ran P, Shen H, Wen F, Huang K, Yao W, Sun T, Shan G, Yang T, Lin Y, Wu S, Zhu J, Wang R, Shi Z, Zhao J, Ye X, Song Y, Wang Q, Zhou Y, Ding L, Yang T, Chen Y, Guo Y, Xiao F, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study. *Lancet* 2018; 391: 1706–1717.

38. Fang L, Gao P, Bao H, Tang X, Wang B, Feng Y, Cong S, Juan J, Fan J, Lu K, Wang N, Hu Y, Wang L. Chronic obstructive pulmonary disease in China: a nationwide prevalence study. *Lancet Respir. Med.* 2018; 6: 421–430.

39. Osman RK, Mortimer K, Bjune G, Sony AI El. Chronic respiratory disease in adults treated for tuberculosis in Khartoum, Sudan. *Public Heal. Action* 2016; I: 199–204.

40. Ziyada MM. Exploring Tuberculosis Related Stigma in Khartoum-Sudan: A qualitative study. University of Oslo; 2010.

FIGURE 1

Participant flow diagram

FIGURE 2 Prevalence of respiratory symptoms among the study participants. The upper bar represents symptom prevalence in women (n=242) and the lower bar represents symptom prevalence in men (n=353).

FIGURE 3 Estimated Population Prevalence of airway obstruction by age and sex using National Health and Nutrition Examination Survey reference ranges (NHANES) for the Sudanese population in subjects completing standard American Thoracic Society spirometry (n=516). The upper graph represents the prevalence of LLN Stage 1 or higher COPD (Post-BD FEV1/FVC < LLN) and the lower graph represents the prevalence of LLN Stage 2 or higher COPD((Post-BD FEV1/FVC < LLN and post-BD FEV1 < 80% predicted).